CTXR — Citius Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1506251 ·
Last close
$0.55
Market Cap
$15.07M
52W High
$2.19
52W Low
$0.47
ADV30
469,746
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,493,788 | 1,001,945 | -10,011,762 | -8,862,843 | 142,255,198 | 17,007,523 | 66,346,742 |
| Mar 2026 | 1,667,298 | 1,338,420 | -32,194,786 | -21,231,140 | 132,540,579 | 4,590,174 | 63,456,026 |
| Dec 2025 | 3,944,111 | 3,154,903 | -9,019,208 | -8,220,785 | 140,391,730 | 7,721,393 | 46,923,760 |
| Sep 2025 | 0 | — | -8,437,309 | -7,959,288 | 130,938,025 | 4,252,290 | 53,410,425 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-31,596,253
Investing CF
$-5,000,000
Financing CF
$46,910,017
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.40
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-268,256,054
Inventory
$22,659,590
Receivables
$1,079,055
ST Investments
—
EBIT TTM
$-54,433,292
Pretax Income TTM
$-54,889,643
Interest Exp TTM
$456,351
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,105,197
EBITDA
$-53,851,096
Free Cash Flow
$-36,803,784
Enterprise Value
$15,414,862
Total Cash
$17,007,524
Total Debt
$7,177,118
Shares Out
27,452,570
Trailing EPS
$-1.75
Book Value
$2.43
ROE
-81.1%
ROA
-26.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -38,525,608 | -37,433,911 | 130,938,025 | 53,410,425 | 67,550,178 | -26,552,738 |
| Sep 2024 | 0 | -41,995,681 | -39,138,839 | 116,651,751 | 42,549,921 | 70,077,450 | -28,201,375 |
| Sep 2023 | 0 | -36,732,018 | -32,542,912 | 103,611,150 | 12,179,662 | 90,831,108 | -29,060,212 |
| Sep 2022 | 0 | -33,316,045 | -33,640,646 | 113,999,302 | 10,573,057 | 102,825,865 | -28,361,256 |
| Sep 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.44
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DARE | Dare Bioscience, Inc. | $14.75M | $0.75 | — |
| ALLR | Allarity Therapeutics, Inc. | $15.41M | $0.97 | — |
| HIND | Vyome Holdings, Inc | $14.25M | $2.03 | — |
| KTTA | Pasithea Therapeutics Corp. | $16.04M | $0.48 | — |
| SYBX | SYNLOGIC, INC. | $14.09M | $1.15 | — |
News headlines (Yahoo Finance, 1h cache)
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
2026-08-12 12:00 · Yahoo
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
2026-05-24 11:49 · Yahoo
We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon
2026-04-21 17:09 · Yahoo
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
2026-04-24 12:00 · Yahoo
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
2026-03-31 13:11 · Yahoo
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
2026-04-24 20:30 · Yahoo
Citius Pharmaceuticals Secures $5M Through Equity Offering
2026-04-24 14:48 · Yahoo
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
2026-09-03 12:30 · Yahoo
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-08-14 20:30 · Yahoo
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-08-14 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.